Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 15/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | MMP13 | P45452 | 3/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119185 | 0.89 | TRPM8 (1.00) | TRPM8KDM4EALDH1A1HPGD | |
| SCHEMBL119114 | 0.85 | KDM4E (0.66) | TRPM8KDM4EALDH1A1MMP1MMP9 | |
| SCHEMBL27866030 | 0.85 | TRPM8 (0.81) | TRPM8KDM4EALDH1A1MMP1MMP9 | |
| SCHEMBL120885 | 0.84 | TRPM8 (0.81) | TRPM8 | |
| SCHEMBL119844 | 0.83 | TRPM8 (0.68) | TRPM8 | |
| SCHEMBL118337 | 0.83 | TRPM8 (0.81) | TRPM8 | |
| SCHEMBL119865 | 0.82 | ALDH1A1 (0.66) | TRPM8KDM4EALDH1A1MMP9MMP13 | |
| SCHEMBL118428 | 0.80 | TRPM8 (0.60) | TRPM8KDM4EALDH1A1 | |
| SCHEMBL13064479 | 0.79 | ALDH1A1 (0.70) | TRPM8KDM4EALDH1A1HPGD | |
| SCHEMBL119747 | 0.78 | TRPM8 (0.79) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427810-A | Sulfamoylbenzoic acid derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | TRPM8 1/4885KDM4E 2411/4885ALDH1A1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.